EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparative Analysis Between Olink‐PEA and Alamar‐NULISA Proteomic Technologies Applied to a Critically Ill COVID‐19 Cohort

Sara Taleb iD, Nisha Stephan, Sareena Chennakkandathil, Muhammad Umar Sohail, Sondos Yousef, Hina Sarwath, Muna Al-Noubi, Karsten Suhre, Ali Ait Hssain, Frank Schmidt

PROTEOMICS · 2025-12 · 25 (23) · 6-15

DOI: 10.1002/pmic.202400456 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift PROTEOMICS, online erschienen am 10.02.2025. Verfasst von Sara Taleb und 9 weiteren Autor:innen. Beteiligte Einrichtung: Proteomics Core, Weill Cornell Medicine, Doha, Qatar. Hauptthemen laut MEDLINE: COVID-19, Proteomics, Blood Proteins, Proteome. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Medical Research Center (MRC), Hamad Medical Corporation (HMC), Biomedical Research Program at Weill Cornell Medicine in Qatar (WCM-Q).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We aim to verify and validate low‐abundant plasma proteins from severe COVID‐19 cases and controls through a comparative analysis between Olink and Alamar performances. Eighty‐three severe cases and 44 controls were measured for proteomics using three Olink panels and one Alamar panel, which share 94 targets. CV, pairwise correlation of intensity signals, and detectability range were compared across platforms. Statistical comparisons were performed using FDR‐adjusted linear models with age as a covariate to construct differential protein abundance volcano plots between cases and controls per platform and heatmaps between our cohort and five public cohorts. Overall, pairwise comparisons ( n = 94) showed strong correlations among cases ( r = 0.82) and controls ( r = 0.7). 60/94 proteins had mutual significance on both platforms; of which 54 showed concordant effect direction, and six showed opposite effect direction (IL‐6R, IL‐1R2, KITLG, TSLP, IL‐17C, and IL‐4R). Alamar verified 80 and 60 targets from cases and controls, respectively, along with 54 differential proteins from Olink. Compared to public cohorts measured by Olink, our Olink data showed consistent findings from 28 proteins, of which 27 were validated by Alamar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19ProteomicsBlood ProteinsProteomeHumansMaleCritical IllnessFemaleSARS-CoV-2Middle AgedAgedCohort StudiesAdultCase-Control Studies

Stichwörter der Autor:innen

AlamarCOVID‐19Olinkcytokinesproteomics

Substanzen

Blood ProteinsProteome

Autor:innen und Institutionen

  • Proteomics Core, Weill Cornell Medicine, Doha, Qatar.
  • Bioinformatics Core, Weill Cornell Medicine, Doha, Qatar.
  • Medical Intensive Care Unit (MICU), Hamad Medical Corporation, Doha, Qatar.
  • Department of Medicine, Weill Cornell Medical College, Doha, Qatar.
  • College of Health and Life Science, Hamad Bin Khalifa University, Doha, Qatar.

ORCID-Profile: Sara Taleb

Förderung

  • Medical Research Center (MRC)
  • Hamad Medical Corporation (HMC)
  • Biomedical Research Program at Weill Cornell Medicine in Qatar (WCM-Q)
  • Qatar Foundation (QF)

Zitieren

APA

Taleb, S., Stephan, N., Chennakkandathil, S., Sohail, M. U., Yousef, S., Sarwath, H., Al-Noubi, M., Suhre, K., Ait Hssain, A., & Schmidt, F. (2025). Comparative Analysis Between Olink‐PEA and Alamar‐NULISA Proteomic Technologies Applied to a Critically Ill COVID‐19 Cohort. PROTEOMICS, 25(23), 6-15. https://doi.org/10.1002/pmic.202400456

Vancouver

Taleb S, Stephan N, Chennakkandathil S, Sohail MU, Yousef S, Sarwath H, et al. Comparative Analysis Between Olink‐PEA and Alamar‐NULISA Proteomic Technologies Applied to a Critically Ill COVID‐19 Cohort. PROTEOMICS. 2025;25(23):6-15. doi:10.1002/pmic.202400456

BibTeX
@article{Taleb2025,
  author = {Taleb, Sara and Stephan, Nisha and Chennakkandathil, Sareena and Sohail, Muhammad Umar and Yousef, Sondos and Sarwath, Hina and Al-Noubi, Muna and Suhre, Karsten and Ait Hssain, Ali and Schmidt, Frank},
  title = {Comparative Analysis Between Olink‐PEA and Alamar‐NULISA Proteomic Technologies Applied to a Critically Ill COVID‐19 Cohort},
  journal = {PROTEOMICS},
  year = {2025},
  volume = {25},
  number = {23},
  pages = {6--15},
  doi = {10.1002/pmic.202400456}
}
Kostenlos starten →